NASDAQ:OVID - Ovid Therapeutics Stock Price, Forecast & News

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics Inc (NASDAQ:OVID) announced its quarterly earnings results on Friday, November, 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.02. View Ovid Therapeutics' Earnings History.

Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ovid Therapeutics.

7 brokers have issued 12-month target prices for Ovid Therapeutics' stock. Their forecasts range from $10.00 to $27.00. On average, they expect Ovid Therapeutics' stock price to reach $14.80 in the next twelve months. This suggests a possible upside of 316.9% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.

News headlines about OVID stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ovid Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Ovid Therapeutics.

Ovid Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 811,800 shares, an increase of 234.6% from the December 15th total of 242,600 shares. Based on an average daily trading volume, of 697,100 shares, the days-to-cover ratio is currently 1.2 days. Currently, 3.6% of the company's shares are sold short. View Ovid Therapeutics' Current Options Chain.

Some companies that are related to Ovid Therapeutics include ImmunoGen (IMGN), Collegium Pharmaceutical (COLL), Homology Medicines (FIXX), Basilea Pharmaceutica (BPMUF), Flexion Therapeutics (FLXN), Akero Therapeutics (AKRO), Emisphere Technologies (EMIS), Retrophin (RTRX), DiaMedica Therapeutics (DMCAF), TherapeuticsMD (TXMD), Omeros (OMER), Axovant Sciences (AXON), Cara Therapeutics (CARA), Vectura Group (VEGPF) and Urogen Pharma (URGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), AcelRx Pharmaceuticals (ACRX), Strongbridge Biopharma (SBBP), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Verastem (VSTM), vTv Therapeutics (VTVT), Cidara Therapeutics (CDTX) and Catalyst Pharmaceuticals (CPRX).

(OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.14%) and Alpine Global Management LLC (0.03%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View Institutional Ownership Trends for Ovid Therapeutics.

OVID stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and Alpine Global Management LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View Insider Buying and Selling for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $3.55.

Ovid Therapeutics has a market capitalization of $169.76 million. The company earns $-51,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe.View Additional Information About Ovid Therapeutics.

The official website for Ovid Therapeutics is http://www.ovidrx.com/.

Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]